Payment overview · 2025
General Payments
$356.61
5 reported records · 3 companies
Healthcare provider profile · identity verified
Marc Robert Watkins, M.D.
Allopathic & Osteopathic Physicians|Preventive Medicine|Preventive Medicine/Occupational Environmental Medicine · NASHVILLE, TN · NPI 1972641074
Verified facts
What the public records show
CMS Open Payments records show Marc Robert Watkins, M.D. received $356.61 in general payments during 2025 across 5 reported records.
Merck Sharp & Dohme LLC accounted for 46.1% of that reported general-payment amount.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GARDASIL 9 as an associated drug or biological on 35573 records involving 25304 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Gardasil 9 by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VAQTA as an associated drug or biological on 1592 records involving 1446 distinct recipient NPIs. Public Medicare Part D data also shows 378 claims for Vaqta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 70775 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRUMENBA as an associated drug or biological on 9375 records involving 6684 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trumenba by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $164.29 | 46.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $125.00 | 35.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $67.32 | 18.9% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $356.61 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | GARDASIL 9 open payments reported associated product |
CMS Open Payments — General Payments 35573 supporting records · 25304 recipient NPIs · example record 1237992212 |
Gardasil 9 · 2024 Exact normalized brand match · 1 Part D row |
229 | 164 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VAQTA open payments reported associated product |
CMS Open Payments — General Payments 1592 supporting records · 1446 recipient NPIs · example record 1237992242 |
Vaqta · 2024 Exact normalized brand match · 1 Part D row |
378 | 349 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
70775 | 70571 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | TRUMENBA open payments reported associated product |
CMS Open Payments — General Payments 9375 supporting records · 6684 recipient NPIs · example record 1228795214 |
Trumenba · 2024 Exact normalized brand match · 1 Part D row |
23 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 71758 | 53846 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 70775 | 70571 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 23521 | 23458 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17508 | 17504 |
| Twinrix | Hepatitis A And B Vaccine/Pf | 5723 | 3615 |
| Havrix | Hepatitis A Virus Vaccine/Pf | 946 | 856 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 447 | 447 |
| Vaqta | Hepatitis A Virus Vaccine/Pf | 378 | 349 |
| M-M-R Ii Vaccine | Measles,mumps,rubella Vacc/Pf | 370 | 333 |
| Gardasil 9 | Hpv Vaccine 9-Valent/Pf | 229 | 164 |
| Menquadfi | Mening Vac A,c,y,w135,c-Tet/Pf | 135 | 128 |
| Typhim Vi | Typhoid Vi Polysacch Vaccine | 119 | 119 |
| Tenivac | Tetanus-Diphtheria Toxoids/Pf | 97 | 97 |
| Naloxone Hcl | Naloxone Hcl | 77 | 71 |
| Heplisav-B | Hepatitis B Vaccine/Cpg1018/Pf | 75 | 52 |
| Bexsero | Meningococcal B Vaccine,4-Comp | 45 | 39 |
| Trumenba | N.Meningitidis B,lipid Fhbp Rc | 23 | 19 |
| Varivax Vaccine | Varicella Vaccine Live/Pf | 19 | 15 |
| Ipol | Poliomyelitis Vaccine, Killed | 18 | 16 |
| Acthib | Haemoph B Poly Conj-Tet Tox/Pf | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Ixiaro | Japanese Encephalitis Vacc/Pf | 11 | suppressed |
| Menveo A-C-Y-W-135-Dip | Mening Vac A,c,y,w-135 Dip/Pf | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $356.61 · 5 records | Merck Sharp & Dohme LLC | — | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Merck Sharp & Dohme LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error